{"id":42410,"date":"2018-06-20T16:57:05","date_gmt":"2018-06-20T15:57:05","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=42410"},"modified":"2018-09-13T09:23:40","modified_gmt":"2018-09-13T08:23:40","slug":"kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/","title":{"rendered":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost?"},"content":{"rendered":"<p class=\"standfirst\">The decline of TB in the developed world began long before the discovery of TB drugs. This is an important lesson for India, says Kanchan Mukherjee<\/p>\n<p><!--more--><a href=\"https:\/\/blogs.bmj.com\/bmj\/files\/2017\/06\/kanchan_mukherjee.jpeg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-39491\" src=\"https:\/\/blogs.bmj.com\/bmj\/files\/2017\/06\/kanchan_mukherjee.jpeg\" alt=\"\" width=\"131\" height=\"146\" \/><\/a><span style=\"font-weight: 400\">Tuberculosis is one of the leading killer diseases in the developing world, with <a href=\"http:\/\/www.who.int\/tb\/publications\/global_report\/en\/\">6.3 million newly diagnosed cases reported in 2016<\/a><\/span><span style=\"font-weight: 400\">. The emergence of multidrug resistant TB (MDR-TB) has further complicated the problem, both in terms of treatment challenges and costs, which is why when bedaquiline was developed as the first new medicine for <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3678673\/\">TB in more than 40 years<\/a>, and clinical trials showed it improved cure rates<\/span><span style=\"font-weight: 400\">, it was broadly welcomed.<\/span><\/p>\n<p><span style=\"font-weight: 400\">India, which has one of the world\u2019s largest populations of TB patients, currently offers the drug as part of second line treatment for patients with MDR-TB at pilot sites <a href=\"http:\/\/iapsm.org\/pdf\/reports\/Annual%20Report%20TB%20India%202016.pdf\">under a conditional access programme<\/a> (CAP)<\/span><span style=\"font-weight: 400\">.\u00a0<\/span><span style=\"font-weight: 400\">However, once the CAP is over, if the Indian government decides to continue providing bedaquiline, it will have to purchase the drug at the local market price. It\u2019s critical that before any wider rollout occurs, the government carries out a thorough budget impact analysis, detailing what it will cost to fund bedaquiline on the national TB control programme. With <a href=\"http:\/\/www.who.int\/tb\/publications\/GTBcorporate_factsheet.pdf\">India bearing a large part of the world\u2019s burden of MDR-TB<\/a><\/span><span style=\"font-weight: 400\">, the way the country tackles this disease will have a substantial impact on the global movement for TB elimination.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The\u00a0current cost of a drug-sensitive TB treatment course as per the national guidelines is around (US)$50 in India, while the cost of the treatment course of MDR-TB, including bedaquiline and other second line drugs, is estimated to be around $3500<\/span><span style=\"font-weight: 400\">. <\/span><span style=\"font-weight: 400\">Considering that there are around\u00a0<a href=\"https:\/\/www.tbfacts.org\/tb-statistics-india\/\">150 000 cases of MDR-TB in India<\/a><\/span><span style=\"font-weight: 400\">\u2014a figure which is <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28499828\">projected to rise<\/a><\/span><span style=\"font-weight: 400\">\u2014the government will need to take a hard and analytical look at the costs of rolling bedaquiline out.<\/span><\/p>\n<p><span style=\"font-weight: 400\">It\u2019s easy to see why rolling out bedaquiline would be politically popular. For a policy maker, the introduction of a new drug offers maximum visibility in a short span of time. However, it doesn\u2019t address the structural problems that are also responsible for the spread of TB in India: for example, overcrowded housing, poor ventilation, poor nutrition, etc. Countries that have managed to eradicate TB were able to make great gains by investing in <a href=\"https:\/\/watermark.silverchair.com\/280327.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAZ4wggGaBgkqhkiG9w0BBwagggGLMIIBhwIBADCCAYAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMBCMAzO1ps7gYn7dqAgEQgIIBUdyEYMoj1V9EiNn6-W7GAtjE2C3kCKFxh4LMWFp7aCuszr7-Yinyik-6bO69cZ9WL3-QgZGyEg7IMO0QM0GEWIqRnO8TaWxy9XByjuRR-9Z9cOlby72xURi3QdMSZ8BrTxDY1nKAysyUfCD7jNn4OhjytZcOuAgHme68m4FMdCBgXiDda4wHGzQoDmYh5OgWExX3omstrqmteRKfXbhBUKlZEje8qjfJpyjj7w2z1oYS4gaFmNSmgjG9yG0LfK6P2Shi9iMDE-ySRdw6AmQQrkqquGqfrCk9wVUsiqFVzGQaW5W4axPIILF7-b3LSmWMcRBKpkN67rv0m9YYFu1x21DQ5nh4T2_Hntqf3Y3N9j9gK2hUODIKJZvzFmy1HlwQy577k7r3vrWQepgxTv3oCfnt8V9q_ZD_nkwkUqKy-KEwicKjws4kq_oRFEBTU0tEpVk\">public health measures that addressed these social determinants<\/a><\/span><span style=\"font-weight: 400\">. <\/span><span style=\"font-weight: 400\">The decline of TB in the developed world began long before the discovery of TB drugs. This is an important lesson for India. <\/span><\/p>\n<p><span style=\"font-weight: 400\">There is a huge opportunity cost attached to investing in bedaquiline in India to treat MDR-TB. Bedaquiline may help patients already suffering from MDR-TB, but at its current price, the cost implications are huge if it is to be made part of the national programme for TB control. If it is to be at all feasible, the price of the drug will have to be brought down substantially. <\/span><\/p>\n<p><span style=\"font-weight: 400\">Furthermore, in the rush to roll out a new intervention, we mustn&#8217;t forget that there are cost effective strategies beyond drugs, which could help prevent the development of multidrug resistance. For example, incentivising appropriate prescription practices for standard TB treatment and improving compliance\/adherence rates. Investing in robust, multisectoral prevention strategies like these would offer much better and long lasting value for money in the Indian context.<\/span><\/p>\n<p><em><strong><span class=\"il\">Kanchan<\/span> Mukherjee<\/strong> is a medical doctor who specialises\u00a0in public health, health policy, and health economics. He is currently a professor at the Tata Institute of Social Sciences, Mumbai.<\/em><\/p>\n<p><strong>Competing interests:<\/strong>\u00a0I have read and understood BMJ policy on declaration of interests and declare the following interests: None.<\/p>\n<p>Editor&#8217;s note:\u00a0<i>The BMJ<\/i>\u00a0changed the first sentence of the third paragraph of this article on 13 September 2018. The original sentence did not state explicitly that the $3500 cost quoted includes second line drugs as well as bedaquiline. The rewording addresses a concern raised in correspondence by Johnson &amp; Johnson, the company that manufactures bedaquiline.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The decline of TB in the developed world began long before the discovery of TB drugs. This is an important lesson for India, says Kanchan Mukherjee [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":42419,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447],"tags":[],"class_list":["post-42410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-india"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ\" \/>\n<meta property=\"og:description\" content=\"The decline of TB in the developed world began long before the discovery of TB drugs. This is an important lesson for India, says Kanchan Mukherjee [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-20T15:57:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-09-13T08:23:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"540\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost?\",\"datePublished\":\"2018-06-20T15:57:05+00:00\",\"dateModified\":\"2018-09-13T08:23:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/\"},\"wordCount\":654,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/tb_india_poster.jpg\",\"articleSection\":[\"South Asia\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/\",\"name\":\"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/tb_india_poster.jpg\",\"datePublished\":\"2018-06-20T15:57:05+00:00\",\"dateModified\":\"2018-09-13T08:23:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/tb_india_poster.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/tb_india_poster.jpg\",\"width\":540,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/20\\\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/","og_locale":"en_US","og_type":"article","og_title":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ","og_description":"The decline of TB in the developed world began long before the discovery of TB drugs. This is an important lesson for India, says Kanchan Mukherjee [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2018-06-20T15:57:05+00:00","article_modified_time":"2018-09-13T08:23:40+00:00","og_image":[{"width":540,"height":350,"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg","type":"image\/jpeg"}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost?","datePublished":"2018-06-20T15:57:05+00:00","dateModified":"2018-09-13T08:23:40+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/"},"wordCount":654,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg","articleSection":["South Asia"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/","url":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/","name":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost? - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg","datePublished":"2018-06-20T15:57:05+00:00","dateModified":"2018-09-13T08:23:40+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/tb_india_poster.jpg","width":540,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/20\/kanchan-mukherjee-bedaquiline-multidrug-resistant-tb-india-cost\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Kanchan Mukherjee: Bedaquiline for multidrug resistant TB in India\u2014at what cost?"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=42410"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42410\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media\/42419"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=42410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=42410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=42410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}